Bibliography
- Grube E , BuellesfeldL. Everolimus for stent-based intracoronary applications. Rev. Cardiovasc. Med.5(Suppl. 2), S3–S8 (2004).
- Serruys PA , OrmistonJA, OnumaYet al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897–910 (2009).
- Landesman Y , SvrzikapaN, CognettaAet al. In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence1, 16 (2010).
Patents
- Advanced Cardiovascular Systems Inc.: US7867549 (2011).
- Biolex Therapeutics Inc.: US7867518 (2011).
Websites
- CPEX to be acquired by FCB I Holdings Inc. for US$27.25 per share in cash. www.cpexpharm.com/files/pdfs/pr/2011/pr-010411.pdf (Accessed on 17 January 2011)
- CPEX Pharmaceuticals. www.cpexpharm.com/index.htm (Accessed on 17 January 2011)
- Auxilium Pharmaceuticals. www.auxilium.com/AboutAuxilium/Default.aspx (Accessed on 17 January 2011)
- New oral biologics delivery company, Entrega, announces strategic partnership with Pharma. www.enlightbio.com/news/new-oral-biologics-delivery-company-entrega-announces-strategic-partnership-with-pharma-84/ (Accessed on 21 January 2011)
- Enlight Biosciences. www.enlightbio.com/content/about-enlight/ (Accessed on 21 January 2011)
- sanofi-aventis and Avila Therapeutics sign global alliance to develop targeted covalent oncology drugs. www.avilatx.com/news/2010_1220_Avila_SanofiAventis_PressRelease.pdf (Accessed on 21 January 2011)
- Novo Nordisk A/S and Emisphere Technologies, Inc. announce license agreement to develop oral formulation of insulin for diabetes. http://ir.emisphere.com/releasedetail.cfm?ReleaseID=538138 (Accessed on 21 January 2011)
- Emisphere. www.emisphere.com/index.html (Accessed on 24 January 2011)
- Spirogen Ltd. announces a research collaboration and license agreement with Genentech for the discovery and development of antibody–drug conjugates. www.spirogen.com/news/press-archive.php?id=448 (Accessed on 21 January 2011)
- Technologies section on Spirogen. www.spirogen.com/technologies/proprietary-pbds.php (Accessed on 21 January 2011)
- Seattle Genetics announces antibody–drug conjugate collaboration with Pfizer. http://investor.seagen.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1513501&highlight= (Accessed on 21 January 2011)
- Sutro Biopharma forges partnership with Pfizer for discovery, development and commercialization of novel peptide-based therapeutics. www.sutrobio.com/news/110107pr.html (Accessed on 17 January 2011)
- Sutro Biopharma. www.sutrobio.com/about/index.html (Accessed on 17 January 2011)
- Dance Pharma, Aerogen Ltd. to develop proprietary inhaled insulin device. www.dancepharma.com/pr-011211.html. (Accessed on 21 January 2011)
- Aerogen Ltd. OnQ technology. http://aerogen.com/how-does-it-work.html (Accessed on 21 January 2011)
- LifeCycle Pharma raises US$85 million to bankroll LCP-Tacro. Press release on scrip website. www.scripintelligence.com/home/LifeCycle-Pharma-raises-85M-to-bankroll-LCP-Tacro-308228 (Accessed on 24 January 2010)
- LifeCycle Pharma. www.lcpharma.com/about.cfm (Accessed on 24 January 2011)
- NextWave Pharmaceuticals secures US$45 million in financing. www.nextwavepharma.com/news/NextWave_press_release_11Jan2011.pdf (Accessed on 24 January 2011)
- NextWave Pharmaceuticals announces launch of NEXICLON™ XR – first extended-release, once-daily clonidine oral suspension and tablet. www.nextwavepharma.com/news/Nexiclon_XR_press%20release_06Jan2011.pdf (Accessed on 24 January 2011)
- Tris Pharma. www.trispharma.com (Accessed on 24 January 2011)
- FDA approval for Abstral® (Fentanyl) sublingual tablets – US launch planned for Q1 2011. www.orexo.com/en/Investor-Relations/Press-releases/?guid=536217 (Accessed on 24 January 2011)
- Abbott receives Œ Mark Approval for world‘s first drug-eluting bioresorbable vascular scaffold for treatment of coronary artery disease. www.abbott.com/PressRelease/2011Jan10.htm (Accessed on 28 January 2011)
- XIENCE PRIME™ everolimus-eluting coronary stent system section. www.abbottvascular.com/int/xience-prime.html (Accessed on 1 February 2011)
- Alnylam demonstrates RNAi in man with systemically delivered RNAi therapeutics. http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1512322&highlight= (Accessed on 28 January 2011)
- Excaliard announces positive results from three Phase II clinical trials for EXC 001, showing significant improvement in both hyper-trophic and fine-line scarring. http://excaliard.com/news/PressReleaseExcaliardJanuary2011.pdf (Accessed on 29 January 2011)
- Pacira Pharmaceuticals presents new data from EXPAREL Phase III study at the Orthopaedic Research Society‘s 57th Annual Meeting. www.pacira.com/pdf/01-13-11-New-Data.pdf (Accessed on 29 January 2011)
- A Phase III, randomized, placebo-controlled trial of EXPAREL™, an extended release bupivacaine local analgesic, in bunionectomy. Poster on pacira pharmaceuticals website. www.pacira.com/pdf/01-13-11-Poster.pdf (Accessed on 29 January 2011)
- Section on DepoFoam technology on Pacira Pharmaceuticals website. www.pacira.com/platform-depofoam-about.php (Accessed on 29 January 2011)
- Wikipedia entry on the Guidant Corporation. http://en.wikipedia.org/wiki/Guidant (Accessed on 29 January 2011)
- Biolex Therapeutics. Section on Locteron®. www.biolex.com/locteron-.htm (Accessed on 29 January 2011)
- Biolex Therapeutics enters into agreement to acquire full Locteron® commercial rights. www.biolex.com/pdfs/Biolex%20Acquires%20Full%20Rights%20to%20Locteron%20-%20October%206%202008.pdf (Accessed on 29 January 2011)
- OctoPlus. Section on PolyActive®. http://observer.octoplus.nl/index.cfm/octoplus/drug-delivery/polyactive/index.cfm (Accessed on 29 January 2011)